Jens Faunø Thrane1,2, Therese Ovesen3,4. 1. a Department of Otorhinolaryngology, Head & Neck Surgery , Aarhus University Hospital , Aarhus , Denmark. 2. b Department of Otorhinolaryngology, Head & Neck Surgery , Aalborg University Hospital , Aalborg , Denmark. 3. c Department of Clinical Medicine , Aarhus University , Aarhus , Denmark. 4. d Department of Otorhinolaryngology, Head & Neck Surgery , Region Hospital Holstebro , Holstebro , Denmark.
Abstract
Background: Necrotizing soft tissue infection (NSTI) is a rare and potentially life-threatening disease. Rapid surgical intervention, antibiotics and intensive care are the mainstay of treatment. Hyperbaric oxygen therapy (HBOT) is used as adjuvant therapy in some centres but there is a lack of research-based evidence of efficacy. Methods: Following the PRISMA guideline we conducted a systematic review on the efficacy of HBOT on NSTI with mortality as primary outcome. Through January 2019 major databases were searched and relevant literature assessed. The criteria for study inclusion were research of any design and any period of time comparing HBOT vs. non-HBOT in a population of NSTI-patients. Studies were analysed using the modified Delphi method and risk of bias in non-randomized studies - of interventions tool. Relative risk (RR) on mortality was calculated for each study individually. Results: A number of 1733 studies were identified through database search. Ultimately, 21 studies were included of which 19 were case series with a control group. The majority of the studies performed poor in quality assessment and all featured a high to critical risk of bias. The association of HBOT on mortality was generally reported as positive, however, the results should be considered with great scepticism. Conclusions: The evidence of HBOT in NSTI is poor and biased. There is a strong need for randomized controlled trials (RCTs) to shed light on a potential life-saving treatment.
Background: Necrotizing soft tissue infection (NSTI) is a rare and potentially life-threatening disease. Rapid surgical intervention, antibiotics and intensive care are the mainstay of treatment. Hyperbaric oxygen therapy (HBOT) is used as adjuvant therapy in some centres but there is a lack of research-based evidence of efficacy. Methods: Following the PRISMA guideline we conducted a systematic review on the efficacy of HBOT on NSTI with mortality as primary outcome. Through January 2019 major databases were searched and relevant literature assessed. The criteria for study inclusion were research of any design and any period of time comparing HBOT vs. non-HBOT in a population of NSTI-patients. Studies were analysed using the modified Delphi method and risk of bias in non-randomized studies - of interventions tool. Relative risk (RR) on mortality was calculated for each study individually. Results: A number of 1733 studies were identified through database search. Ultimately, 21 studies were included of which 19 were case series with a control group. The majority of the studies performed poor in quality assessment and all featured a high to critical risk of bias. The association of HBOT on mortality was generally reported as positive, however, the results should be considered with great scepticism. Conclusions: The evidence of HBOT in NSTI is poor and biased. There is a strong need for randomized controlled trials (RCTs) to shed light on a potential life-saving treatment.
Authors: Laila Schneidewind; Petra Anheuser; Sandra Schönburg; Florian M E Wagenlehner; Jennifer Kranz Journal: Urol Int Date: 2020-12-07 Impact factor: 2.089
Authors: Omar Feres; Marley Ribeiro Feitosa; José Joaquim Ribeiro da Rocha; Juliana Mamede Miranda; Luciana Egydio Dos Santos; Artur Cury Féres; Hugo Parra de Camargo; Rogério Serafim Parra Journal: Med Gas Res Date: 2021 Jan-Mar
Authors: Susanne Kopp; Wiebke K Peitsch; Assen Mladenov; Katharina Diehl; Oliver Müller; Christian von Heymann Journal: World J Emerg Surg Date: 2022-08-05 Impact factor: 8.165
Authors: Maximilian Leiblein; Nils Wagner; Elisabeth H Adam; Johannes Frank; Ingo Marzi; Christoph Nau Journal: Orthop Surg Date: 2020-10-04 Impact factor: 2.071